Form 4: Neumora Therapeutics Head of R&D Sells Shares to Cover Tax Obligations

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of common stock on September 12, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold 32,948 shares of common stock on September 12, 2024.
• The sale was executed at a weighted average price of $11.4321 per share, with individual trades ranging from $11.22 to $11.6050.
• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2024, to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following the transaction, Lenz still beneficially owns 369,993 shares of Neumora Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax purposes) by an insider, which is neither particularly positive nor negative. The use of a 10b5-1 plan mitigates concerns about insider trading.

Industry Context

Sales by company insiders are a common occurrence, often related to tax obligations or diversification strategies. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The sale of shares by a company insider could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates